Three CDK 4/6 inhibitors palbociclib (Ibrance®), ribociclib (Kisqali®), and abemaciclib (Verzenio®) are FDA approved for treating people with hormone receptor-positive, HER2-negative MBC. New information suggests that these drugs may work differently in different people. Clinical trials are testing these drugs in people with HER2-positive breast cancer and in people with triple-negative breast cancer. In addition, the benefits of CDK 4/6 inhibitors may differ according to body mass index and ethnicity.
Read below for an introduction to CDK 4/6 inhibitors and for new information about the use of these drugs in various groups of people with MBC.
Introduction to CDK 4/6 Inhibitors
- Breastcancer.org: About Taking CDK 4/6 Inhibitors and Managing Side Effects
- Healio: CDK 4/6 Inhibitors Plus Endocrine Therapy in Breast Cancer
CDK 4/6 Inhibitors in Different Populations of People with MBC
- OncLive: CDK 4/6 Inhibitors in HER2+ and Triple-Negative Breast Cancers
- Practice Update: Impact of BMI on Progression-Free Survival in People With MBC Treated With CDK 4/6 Inhibitors
- Journal Article: Effect of CDK 4/6 Inhibitors in Asian Populations
- Practice Update (Create a free account to view): Racial Disparities in Overall Survival After the Introduction of CDK4/6 Inhibitors for Patients With HR+/HER2- Metastatic Breast Cancer
Clinical Trials That Include CDK Inhibitors
- Metastatic Trial Search: MBC Trials That Include CDK Inhibitors
- Solid Tumor Trials: Trials That May Include CDK Inhibitors
Last Modified on December 12, 2023